Product Program year 2020 Source: CMS Open Payments

Qtern

Drug Cardiovascular And Metabolism

NDC 0310-6780-30

Open in the dashboard

General payments

$2,096

31 payments

Research payments

$591,327

21 payments

Through program year 2020, $2,096 in general payments and $591,327 in research payments were reported against Qtern (Cardiovascular And Metabolism).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2020 General $39 2
2020 Research $15,637 3
2019 General $2,057 29
2019 Research $575,690 18

Breakdown

Who paid General payments · program years 2019–2020
  1. AstraZeneca Pharmaceuticals LP $2,096 31 payments
Top recipients General payments · program year 2020
  1. Karelina Muguercia Family Medicine · Orlando, FL $20 50% · 1 payment
  2. Mark Chin Lenn Family Medicine · Hollywood, FL $20 50% · 1 payment

Each share is of general payments naming this product in 2020.

Specialties paid General payments · program year 2020
  1. Family Medicine $39 100% · 2 practitioners

Each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2020
  1. Florida $39 100% · 2 recipients

Each share is of general payments naming this product in 2020 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

905

Prescriptions dispensed, refills included

Drug cost

$453,092

Paid at the pharmacy, in all

Prescribers

43

With 11 or more claims of it

Medicare Part D drugs matched to QTERN, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Qtern Dapagliflozin/Saxagliptin Hcl Same name 43 905 $453,092

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 43 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Silvia Cuadra Mongalo Endocrinology FL 117 $54,062 None on record
Khalid Khan Internal Medicine VA 64 $27,390 None on record
Ashley Briggs Nurse Practitioner FL 54 $22,555 None on record
Gerald Miceli Endocrinology FL 44 $22,380 None on record
Ketsia Celestin Family Practice FL 40 $26,247 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 43 with Patron
31 general · 21 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record